<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756235</url>
  </required_header>
  <id_info>
    <org_study_id>P13-683</org_study_id>
    <nct_id>NCT01756235</nct_id>
  </id_info>
  <brief_title>Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice</brief_title>
  <acronym>PACE</acronym>
  <official_title>Physical ACtivity in patiEnts With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (PACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate physical activity and its changes in participants
      with rheumatoid arthritis (RA) who were treated with adalimumab therapy in clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This post-marketing observational study was conducted in a multi-country, multi-center and
      single-arm format. Data were collected prospectively. Adult participants with diagnosis of RA
      who were assigned for treatment with adalimumab (HumiraÂ®) were eligible for participation.
      During this period four follow-up visits were planned for observation of the participant and
      documentation of data. Ideally, these visits should have been performed approximately 3 (V1),
      6 (V2), 9 (V3) and 12 (V4) months after the baseline visit (V0).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score</measure>
    <time_frame>Month 0 (baseline) and Month 12 (Last Observation Carried Forward (LOCF))</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Physical Activity SQUASH Score</measure>
    <time_frame>Month 3, Month 6 and Month 9</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SQUASH-A Scores</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>SQUASH subscores capture physical activity. SQUASH-A subscore captures commuting activities, with scores ranging from 0 to 4082.400. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SQUASH-B Scores</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>SQUASH subscores capture physical activity. SQUASH-B subscore captures leisure time activities, with scores ranging from 0 to 6123.600. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SQUASH-C Scores</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>SQUASH subscores capture physical activity. SQUASH-C subscore captures house-hold activities, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SQUASH-D Scores</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>SQUASH subscores capture physical activity. SQUASH-D subscore captures activity at work and school, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Disease Activity Index - 28 Joints (DAS28) Score</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein, and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Disease Remission (DAS28&lt;2.6)</measure>
    <time_frame>Month 0, Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>Remission is defined as DAS28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Low Disease Activity State (LDAS, DAS28&lt;3.2)</measure>
    <time_frame>Month 0, Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>LDAS is defined as DAS28 of less than 3.2. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categories' SQUASH Scores in Participants in Remission or LDAS</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categories' SQUASH Scores in Participants Those Who Did Not Attain Remission or LDAS</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
    <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores range from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from baseline in the overall score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) and DAS28 Scores</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the DAS28 measures disease activity. In order to evaluate the relationship between physical function and disease activity (as measured by the two scales), Pearson correlation coefficients were calculated for the SQUASH scores and the DAS28. A decrease in physical functioning is likely to be connected to stronger disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) and HAQ-DI Scores</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the HAQ-DI measures physical functioning. In order to evaluate the relationship between physical function and physical activity (as measured by the both scales), Pearson correlation coefficients were calculated for the SQUASH scores and the HAQ-DI. A decrease in physical functioning is likely to prohibit physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Age Categories</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Gender</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Education</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Occupation</measure>
    <time_frame>Month 0 and Month 12 LOCF</time_frame>
    <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">462</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Participants with Rheumatoid Arthritis</arm_group_label>
    <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consisted of participants with rheumatoid arthritis (RA) who were treated
        with adalimumab as per locally approved label and prescription guidelines. The decision to
        be treated with adalimumab had to be independent from study inclusion.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Had rheumatoid arthritis (RA) and is eligible to start and/or continue adalimumab
             therapy according to the local product label and prescription guidelines

          -  Had been started on adalimumab therapy no more than one (1) month prior to the study
             enrolment

          -  Had negative result of tuberculosis (TB) screening test or was receiving TB
             prophylaxis as per local guidelines

          -  Had provided written Authorization to the investigator to use and/or disclose personal
             and/or health data, or Informed Consent if requested by the Local Regulations

        Exclusion Criteria:

          -  Was unable to walk either due to RA or a comorbid condition

          -  Was unable to perform basic self-care activities

          -  Had contraindications for treatment with adalimumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Smirnova, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
  </removed_countries>
  <link>
    <url>http://www.rxabbvie.com</url>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2012</study_first_posted>
  <results_first_submitted>October 26, 2016</results_first_submitted>
  <results_first_submitted_qc>January 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2017</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-marketing observational study (PMOS) Protocol</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Physical Activity</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>HumiraÂ®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 462 participants were enrolled: 460 were in the main analysis set (MAS) population; 2 were excluded from MAS, as adalimumab treatment was not documented within this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Participants With Rheumatoid Arthritis</title>
          <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="462"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="460"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adalimumab Treatment was not Documented</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analyses accounts for main analysis set (MAS) population (all participants who received at least 1 dose of study drug).</population>
      <group_list>
        <group group_id="B1">
          <title>Participants With Rheumatoid Arthritis</title>
          <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="460"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 0 (baseline) and Month 12 (Last Observation Carried Forward (LOCF))</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="870.0" spread="4517.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Physical Activity SQUASH Score</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 3, Month 6 and Month 9</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Physical Activity SQUASH Score</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=356)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454.9" spread="3553.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.2" spread="3565.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611.3" spread="4130.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SQUASH-A Scores</title>
        <description>SQUASH subscores capture physical activity. SQUASH-A subscore captures commuting activities, with scores ranging from 0 to 4082.400. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SQUASH-A Scores</title>
          <description>SQUASH subscores capture physical activity. SQUASH-A subscore captures commuting activities, with scores ranging from 0 to 4082.400. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-91.6" spread="950.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=327)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.7" spread="957.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1052.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=265)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="880.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=382)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.7" spread="1043.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SQUASH-B Scores</title>
        <description>SQUASH subscores capture physical activity. SQUASH-B subscore captures leisure time activities, with scores ranging from 0 to 6123.600. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SQUASH-B Scores</title>
          <description>SQUASH subscores capture physical activity. SQUASH-B subscore captures leisure time activities, with scores ranging from 0 to 6123.600. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=359)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.5" spread="2729.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497.9" spread="2375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=277)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.9" spread="2720.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=257)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831.3" spread="3450.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=375)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578.0" spread="3131.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SQUASH-C Scores</title>
        <description>SQUASH subscores capture physical activity. SQUASH-C subscore captures house-hold activities, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SQUASH-C Scores</title>
          <description>SQUASH subscores capture physical activity. SQUASH-C subscore captures house-hold activities, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=364)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="1507.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=325)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.6" spread="1516.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" spread="1590.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=261)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.4" spread="1750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=379)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.9" spread="1725.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SQUASH-D Scores</title>
        <description>SQUASH subscores capture physical activity. SQUASH-D subscore captures activity at work and school, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SQUASH-D Scores</title>
          <description>SQUASH subscores capture physical activity. SQUASH-D subscore captures activity at work and school, with scores ranging from 0 to 3402.000. The SQUASH subscores have non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=370)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="823.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=330)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="1102.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.2" spread="1263.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.2" spread="1733.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=382)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" spread="1536.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Disease Activity Index - 28 Joints (DAS28) Score</title>
        <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein, and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Disease Activity Index - 28 Joints (DAS28) Score</title>
          <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein, and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt;5.1 indicates high disease activity, a DAS28 score &lt;3.2 indicates low disease activity, and a DAS28 score &lt;2.6 indicates clinical remission.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=433)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Disease Remission (DAS28&lt;2.6)</title>
        <description>Remission is defined as DAS28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
        <time_frame>Month 0, Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Disease Remission (DAS28&lt;2.6)</title>
          <description>Remission is defined as DAS28 of less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N=459)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=434)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Low Disease Activity State (LDAS, DAS28&lt;3.2)</title>
        <description>LDAS is defined as DAS28 of less than 3.2. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
        <time_frame>Month 0, Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Low Disease Activity State (LDAS, DAS28&lt;3.2)</title>
          <description>LDAS is defined as DAS28 of less than 3.2. The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0 (N=459)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (N=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=362)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=434)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categoriesâ SQUASH Scores in Participants in Remission or LDAS</title>
        <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categoriesâ SQUASH Scores in Participants in Remission or LDAS</title>
          <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (Month 3, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473.3" spread="3417.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 3, N=204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.5" spread="609.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 3, N=200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438.3" spread="2480.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 3, N=200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" spread="1617.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 3, N=205)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="762.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 6, N=181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="979.8" spread="3567.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 6, N=187)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="724.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 6, N=183)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.0" spread="2383.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 6, N=186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.5" spread="1518.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 6, N=189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="1142.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 9, N=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1209.8" spread="4126.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 9, N=165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.3" spread="874.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 9, N=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="707.2" spread="2815.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 9, N=165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.9" spread="1713.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 9, N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.4" spread="1298.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 12, N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1912.4" spread="4592.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 12, N=171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" spread="724.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 12, N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1158.7" spread="3168.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 12, N=169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.7" spread="1898.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 12, N=171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.6" spread="1905.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 12 LOCF, N=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1494.8" spread="4513.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 12 LOCF, N=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4" spread="860.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 12 LOCF, N=211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964.5" spread="3127.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 12 LOCF, N=212)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367.5" spread="1808.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 12 LOCF, N=214)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" spread="1778.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categoriesâ SQUASH Scores in Participants Those Who Did Not Attain Remission or LDAS</title>
        <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categoriesâ SQUASH Scores in Participants Those Who Did Not Attain Remission or LDAS</title>
          <description>This outcome analyses the quantitative SQUASH score and individual SQUASH scores by DAS28 categories. The quantitative SQUASH score (ranging from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), leisure time activities (SQUASH-B), household activities (SQUASH-C) and activity at work and school (SQUASH-D). The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level. DAS28 categories being assessed are remission (defined as DAS28 of less than 2.6) and LDAS (defined as DAS28 of less than 3.2).The DAS28 is a validated index of rheumatoid arthritis disease activity. Tender joint counts and swollen joint counts across 28 joints, C-reactive protein (CRP), and general health assessed via the visual analog scale (VAS) are included in the DAS28 score. Scores on the DAS28 range from 0 to 10, with higher scores indicating higher disease activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (Month 3, N=157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="434.5" spread="3739.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 3, N=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-134.8" spread="1255.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 3, N=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.9" spread="3029.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 3, N=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="1370.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 3, N=164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.7" spread="893.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 6, N=135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.6" spread="3526.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 6, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.5" spread="1202.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 6, N=136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.9" spread="2325.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 6, N=139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" spread="1512.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 6, N=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="1047.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 9, N=111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-262.1" spread="3995.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 9, N=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-176.9" spread="1245.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 9, N=113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-146.6" spread="2503.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 9, N=116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-125.5" spread="1373.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 9, N=117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.8" spread="1216.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 12, N=88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.7" spread="4924.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 12, N=94)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-117.6" spread="1102.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 12, N=90)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.9" spread="3867.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 12, N=92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="1403.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 12, N=95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="1377.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 12 LOCF, N=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" spread="4420.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 12 LOCF, N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-150.2" spread="1235.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 12 LOCF, N=163)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" spread="3083.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 12 LOCF, N=166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" spread="1599.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 12 LOCF, N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.1" spread="1166.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score</title>
        <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores range from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from baseline in the overall score indicates improvement.</description>
        <time_frame>Month 3, Month 6, Month 9, Month 12 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score</title>
          <description>The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores range from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from baseline in the overall score indicates improvement.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 (N=384)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (N=345)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 (N=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=284)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 LOCF (N=396)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) and DAS28 Scores</title>
        <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the DAS28 measures disease activity. In order to evaluate the relationship between physical function and disease activity (as measured by the two scales), Pearson correlation coefficients were calculated for the SQUASH scores and the DAS28. A decrease in physical functioning is likely to be connected to stronger disease activity.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) and DAS28 Scores</title>
          <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the DAS28 measures disease activity. In order to evaluate the relationship between physical function and disease activity (as measured by the two scales), Pearson correlation coefficients were calculated for the SQUASH scores and the DAS28. A decrease in physical functioning is likely to be connected to stronger disease activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>Correlation coeficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH and DAS28 (Month 0, N=423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH and DAS28 (Month 12 LOCF, N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A and DAS28 (Month 0, N=431)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A and DAS28 (Month 12 LOCF, N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B and DAS28 (Month 0, N=424)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B and DAS28 (Month 12 LOCF, N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C and DAS28 (Month 0, N=429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C and DAS28 (Month 12 LOCF, N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D and DAS28 (Month 0, N=432)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D and DAS28 (Month 12 LOCF, N=386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) and HAQ-DI Scores</title>
        <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the HAQ-DI measures physical functioning. In order to evaluate the relationship between physical function and physical activity (as measured by the both scales), Pearson correlation coefficients were calculated for the SQUASH scores and the HAQ-DI. A decrease in physical functioning is likely to prohibit physical activity.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) and HAQ-DI Scores</title>
          <description>The SQUASH and its subscores are instruments to measure the physical activity level, whereas the HAQ-DI measures physical functioning. In order to evaluate the relationship between physical function and physical activity (as measured by the both scales), Pearson correlation coefficients were calculated for the SQUASH scores and the HAQ-DI. A decrease in physical functioning is likely to prohibit physical activity.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>Correlation coeficient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="430"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (Month 0, N=421)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Month 12 LOCF, N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 0, N=429)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Month 12 LOCF, N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 0, N=422)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Month 12 LOCF, N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 0, N=427)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Month 12 LOCF, N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 0, N=430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Month 12 LOCF, N=385)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Age Categories</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Age Categories</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (&lt;65 years, N=297)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1066.2" spread="4456.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (&gt;=65 years, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.1" spread="4699.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH A (&lt;65 years, N=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="1066.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH A (&gt;=65 years, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.7" spread="956.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH B (&lt;65 years, N=298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770.8" spread="2850.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH B (&gt;=65 years, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-167.8" spread="3972.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH C (&lt;65 years, N=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.5" spread="1779.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH C (&gt;=65 years, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.0" spread="1514.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH D (&lt;65 years, N=302)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.8" spread="1691.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH D (&gt;=65 years, N=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="697.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Gender</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Gender</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (Male, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1500.1" spread="5026.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Female, N=304)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724.9" spread="4388.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Male, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-133.9" spread="1091.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Female, N=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="1032.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Male, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="948.3" spread="3565.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Female, N=305)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493.0" spread="3022.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Male, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.7" spread="1774.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Female, N=309)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.4" spread="1716.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Male, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.6" spread="1719.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Female, N=312)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="1493.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Education</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Education</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (High School, N=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="831.7" spread="3946.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Lower than High School, N=179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="911.8" spread="5079.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (High School, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.2" spread="926.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Lower than High School, N=184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.5" spread="1158.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (High School, N=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="520.5" spread="2187.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Lower than High School, N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.4" spread="3910.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (High School, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.1" spread="1751.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Lower than High School, N=181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.2" spread="1702.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (High School, N=198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.4" spread="1644.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Lower than High School, N=184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="1415.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Occupation</title>
        <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
        <time_frame>Month 0 and Month 12 LOCF</time_frame>
        <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Rheumatoid Arthritis</title>
            <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categoriesâ SQUASH Scores) Influenced by Occupation</title>
          <description>The quantitative SQUASH score (scores range from 0 to 17010.000) is calculated as the sum of subscores that capture physical activity related to commuting activities (SQUASH-A), scores range from 0 to 4082.400, leisure time activities (SQUASH-B), scores range from 0 to 6123.600, household activities (SQUASH-C), scores range from 0 to 3402.000, and activity at work and school (SQUASH-D), scores range from 0 to 3402.000. The SQUASH score and its subscores has non-negative values. Higher values indicate a higher individual activity level.</description>
          <population>Analysis included all participants who received at least one dose of adalimumab with evaluable data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="381"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SQUASH (Manual job, N=184)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1235.3" spread="4853.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH (Non-manual job, N=189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518.4" spread="4160.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Manual job, N=188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.2" spread="977.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-A (Non-manual job, N=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-131.3" spread="1100.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Manual job, N=185)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614.5" spread="3452.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-B (Non-manual job, N=189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.1" spread="2799.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Manual job, N=186)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="456.6" spread="1875.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-C (Non-manual job, N=192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.0" spread="1535.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Manual job, N=188)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="1486.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SQUASH-D (Non-manual job, N=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.7" spread="1590.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected from the time the participant's informed consent was received until 30 days or 5 half-lives following the intake of the last dose of physician-prescribed treatment i.e., up to 12 months.</time_frame>
      <desc>Non serious adverse events were not collected for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Participants With Rheumatoid Arthritis</title>
          <description>Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>NO THERAPEUTIC RESPONSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>HERPES OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LUPUS-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>PHOTODERMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
              <event>
                <sub_title>SKIN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="460"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

